Introduction
============

Major depressive disorder (MDD) is common in elderly patients, with an estimated prevalence of about 3% ([@b1]). It is often associated with physical disability and a high mortality rate ([@b2],[@b3]). Elderly patients are more predisposed to depression than younger patients because of concurrent medical disorders, chronic pain, sadness secondary to life-cycle issues and social isolation ([@b4]). These conditions impair the quality of life in a number of ways, including social and vocational functioning, and emotional and physical well-being.

A large 4-year prospective study suggested that approximately 25% of patients ≥ 65 years with chronic medical illness suffer from depressive symptomatology ([@b5]). Substantial evidence supports the increased prevalence of depression in several chronic medical illnesses, including various forms of vascular disease (cardiovascular, cerebrovascular or peripheral vascular), diabetes mellitus and arthritis. Specifically, patients with cardiovascular disease, diabetes mellitus or arthritis appear to have approximately 2--3 times the risk for depression ([@b6]--[@b8]).

Conversely, depression tends to worsen comorbid medical illnesses and may lead to increased mortality. Depression in patients following myocardial infarction (MI) is a risk factor for mortality at 6 months of hospitalisation ([@b9]) and a significant predictor of 18-month post-MI cardiac mortality ([@b10]). Another study reported that depressive symptoms among women with HIV are associated with HIV disease progression ([@b11]). It has been found from the Systolic Hypertension in the Elderly Programme that depressive symptoms represent a significant risk factor for stroke, MI and death ([@b12]). Similarly, patients with depression and comorbid diabetes mellitus have higher risk for a poor adherence to diet and medication regimens, greater functional impairment and higher healthcare costs than their non-depressed counterparts ([@b13]).

Comorbidity of depression and medical illness in elderly patients leads to increased morbidity and mortality, as well as higher healthcare costs ([@b14]). Therefore, there is a need for a safe, well-tolerated and effective antidepressant in elderly patients with MDD, particularly in those suffering from MDD with chronic medical illness.

Duloxetine hydrochloride is an antidepressant that inhibits both serotonin (5-HT) and norepinephrine (NE) reuptake ([@b15]). The dual-acting mechanism of duloxetine makes it particularly interesting in the treatment of depression with cognitive impairment, as imbalance or deficiency in either 5-HT or NE systems has been found to contribute to cognitive deficits ([@b16],[@b17]). Duloxetine has been shown to treat depression effectively in the elderly population on the basis of pooled subgroup analyses of two previous duloxetine clinical trials in general populations ([@b18]). To confirm the efficacy of duloxetine in elderly patients with MDD, a multicentre, parallel, double-blind, placebo-controlled study of 311 elderly patients ≥ 65 years with MDD was conducted ([@b19]).

Analyses of primary efficacy data from this elderly patient study have shown that duloxetine 60 mg/day improved cognitive function, as evidenced by significantly greater improvement in the composite cognitive score vs. placebo. Duloxetine 60 mg/day also showed significant improvements vs. placebo in the Geriatric Depression Scale (GDS) and 17-Item Hamilton Depression Scale (HAMD~17~) total scores, as well as some pain measures ([@b19]). The present report investigates the impact of medical comorbidity on the efficacy of duloxetine in cognition, depression and quality of life and its tolerability in elderly patients with MDD.

Methods
=======

Study design
------------

This multicentre, randomised, double-blind, placebo-controlled study was conducted in elderly patients with MDD. After a 1-week screening phase, all patients entered a 1-week, double-blind, placebo phase before being randomised to duloxetine 60 mg/day (*n* = 207) or placebo (*n* = 104) for 8 weeks. This was followed by a 1-week, double-blind, discontinuation phase in which the dosage of duloxetine was tapered to 30 mg/day for 4 days. Patients, investigators and all other personnel involved in the conduct of the study were blinded to individual treatment assignments for the duration of the study.

Patients
--------

All patients in this study were ≥ 65 years of age and met diagnostic criteria for MDD as defined in the Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV) ([@b20]). The diagnosis was confirmed by the Mini International Neuropsychiatric Interview ([@b21]), a standardised diagnostic interview based on DSM-IV criteria. Baseline disease severity was defined by patients' scores on the HAMD~17~ ([@b22]). Patients were required to have: HAMD~17~ total score ≥ 18 at visits 1 and 2, a Mini Mental State Examination (MMSE) ([@b23]) score ≥ 20 with or without mild dementia and at least one previous episode of major depression. Patients with a MMSE score of 20--23 were categorised as having mild dementia, while those with a score of ≥ 24 were categorised as having no dementia. Administration of study drug and conduct of the study were in accordance with the Declaration of Helsinki. Each patient provided written informed consent prior to any study procedures.

Patients were excluded for the following reasons: current primary axis I diagnosis other than MDD or mild dementia (including dysthymia or psychotic depression); previous diagnosis of psychotic disorder; organic mental disorder, moderate-to-severe dementia or mental retardation diagnosis; serious or unstable medical illness, psychological condition or clinically significant laboratory abnormality that, in the opinion of the investigator, would compromise participation in this study or be likely to lead to hospitalisation during the course of the study; or ALT, AST or GGT \> 1.5 times upper limit of normal, based on Eli Lilly and Company\'s reference ranges ([@b24]).

Efficacy and tolerability measures
----------------------------------

The primary efficacy measure was a prespecified composite cognitive score based on four cognitive tests: (i) Verbal Learning and Recall Test (VLRT), adapted from the Rey Auditory Verbal Learning Test ([@b25],[@b26]); (ii) Symbol Digit Substitution Test (SDST); (iii) 2-Digit Cancellation Test (2DCT) and (iv) Letter-Number Sequencing Test (LNST). These particular tests were selected because they assess aspects of cognition shown previously to be most impaired in patients with depression, specifically verbal learning and memory, attention, executive function and working memory ([@b27],[@b28]). Moreover, each of these tests has been used extensively in clinical psychopharmacology.

Secondary measures included the GDS and HAMD~17~ total scores, HAMD~17~ response and remission, Visual Analogue Scale (VAS) for pain, Clinical Global Impression-Severity (CGI-S), and the 36-Item Short Form Health Survey (SF-36). HAMD~17~ response was defined as a ≥ 50% decrease in the HAMD~17~ total score from baseline to end-point. Remission was defined as a HAMD~17~ total score of ≤ 7 at end-point. Tolerability measures included adverse events (AEs) reported as the reason for discontinuation and treatment-emergent adverse events (TEAEs).

The composite cognitive score, ranging from 0 to 51, was defined as the sum of: (i) the average number of words recalled on the three learning trials of the VLRT (score 0--15) and the number of words recalled on the delayed recall test of the VLRT (score 0--15); (ii) the fraction of all possible targets correct on the SDST (number correct divided by 133) multiplied by 7 (score 0--7); (iii) the number of targets hit, minus the number incorrect, minus the number of times the patients had to be reminded of the task, divided by the possible number correct (40) on the 2DCT, multiplied by 7 (score 0--7, set to 0 if negative) and (iv) the total score on the LNST (0--21) divided by 3 (score 0--7).

The GDS scale was developed as a basic screening measure for elderly patients with MDD ([@b29],[@b30]). The VAS quantitatively measures overall pain, headache, back pain, shoulder pain, pain interference with daily activities and time in pain while awake ([@b31]).

Cognition measures and the SF-36 were recorded once prior to randomisation and at the last visit of the acute treatment phase. The GDS, HAMD~17~, CGI-Severity and VAS were recorded once prior to randomisation and at every visit of the acute treatment phase.

Description of comorbidity
--------------------------

The medical comorbidity group included patients with one or any of the following three categories of illnesses: vascular (cardiovascular, cerebrovascular or peripheral vascular) disease, diabetes mellitus or arthritis. Medical comorbidities were recorded at baseline to indicate the presence of any of the above illness(es). Indications for comorbidity were based on physical examination, previous diagnosis or patient report.

Statistical analysis
--------------------

All analyses were conducted on an intent-to-treat basis, which is an analysis of the groups to which patients are randomly assigned, even if the patient did not take the assigned treatment, did not receive the correct treatment or otherwise did not follow the protocol. Some analyses were defined *a priori* in the protocol; others were *post hoc*. The term 'significant' for treatment comparisons indicates statistical significance (two-sided p ≤ 0.05). No adjustments for multiple comparisons were made. Throughout this manuscript, 'mean' refers to the raw mean unless the least-squares (LS) mean is specified.

Unless otherwise specified, 'baseline' refers to the last non-missing prerandomisation observation and 'end-point' refers to the last non-missing observation during the treatment phase. Total scores (e.g. composite cognitive score, GDS and HAMD~17~ total scores) were considered to be missing if any of the item scores were missing.

Changes in continuous efficacy variables from baseline to end-point, overall and within subgroups, were analysed using a fixed-effects analysis of covariance (ANCOVA) model that included terms for treatment, investigator and baseline score. This is referred to as a mean change (MC) analysis. Categorical measures, overall and within subgroups, were analysed using Fisher\'s exact test.

The consistency of the effect of duloxetine compared with placebo in comorbidity subgroups, as described in the protocol, was investigated for continuous variables by adding the subgroup and treatment-by-subgroup interaction terms to the ANCOVA model. Corresponding consistency analyses for rates of HAMD~17~ response and remission were performed using a logistic regression model that included terms for treatment, subgroup and treatment-by-subgroup. The consistency for rates of AEs reported as the reason for discontinuation and for TEAEs in patients with comorbidity and without comorbidity were performed using the Breslow-Day test, which assesses the significance of treatment differences in incidence rates between subgroups. Interaction effects were tested at a 0.10 significance level.

TEAEs were defined as events that first occurred or worsened postrandomisation during the treatment phase when compared with the maximum prerandomisation severity. AEs were reported using preferred terms from the Medical Dictionary for Regulatory Activities (MedDRA, MMSO, Reston, VA, USA), version 7.0.

As specified in the protocol, 200 duloxetine- and 100 placebo-treated patients provided 80% power to detect an effect size (difference between MCs in the composite cognitive score divided by the common standard deviation) of 0.35, using a 5%, two-sided significance level and assuming data were available for analyses in 95% of patients. This reflects the power of the study with regard to the primary analysis.

Results
=======

Patient characteristics
-----------------------

Baseline patient characteristics are summarised in [Table 1](#tbl1){ref-type="table"}. Overall, 55.3% of the patients had arthritis, 14.8% had diabetes, 36.0% had vascular comorbidity and 74.9% of patients had at least one of these comorbidities. As expected, mean age was higher in patients with vascular comorbidity vs. without vascular comorbidity and VAS overall pain severity was higher in patients with arthritis vs. without arthritis. Furthermore, patients with vascular comorbidity had more previous episodes of MDD and longer duration of the current episode of MDD; patients with diabetes had higher mean weight, which is clinically relevant and confirms the validity of the sample. It is worth noting that SF-36 physical component summary scores were lower in patients from all subgroups with medical comorbidities, suggesting that a presence of medical comorbidity is associated with worsened patient-reported physical well-being. Most of these characteristics for specific comorbidity also were reflected in the comparisons between those with or without any comorbidity.

###### 

Baseline patient characteristics by comorbidity

                                                                    Any           Arthritis     Diabetes       Vascular                                                
  ----------------------------------------------------------------- ------------- ------------- -------------- ------------- ------------- ------------- ------------- --------------
  Characteristics                                                                                                                                                      
   Gender, female, *n* (%)                                          35 (44.9)     150 (64.4)    63 (45.3)      122 (70.9)    164 (61.9)    21 (45.7)     118 (59.3)    67 (59.8)
   Age, years, mean (SD)                                            71.3 (5.3)    73.4 (5.7)    72.7 (5.6)     73.0 (5.8)    72.9 (5.8)    73.0 (5.1)    72.2 (5.7)    74.1 (5.5)
   Age range, years                                                 65--88        65--89        65--88         65--89        65--89        65--85        65--89        65--86
   Weight, kg, mean (SD)                                            79.1 (17.4)   80.4 (18.4)   80.2 (16.1)    80.0 (19.6)   78.8 (18.0)   87.5 (17.5)   78.9 (18.0)   82.1 (18.2)
   Ethnicity, *n* (%)                                                                                                                                                  
   Caucasian                                                        60 (76.9)     183 (78.5)    105 (75.5)     138 (80.2)    210 (79.2)    33 (71.7)     154 (77.4)    89 (79.5)
   Hispanic                                                         13 (16.7)     35 (15.0)     25 (18.0)      23 (13.4)     37 (14.0)     11 (23.9)     35 (17.6)     13 (11.6)
   African descent                                                  3 (3.8)       14 (6.0)      6 (4.3)        11 (6.4)      15 (5.7)      2 (4.3)       8 (4.0)       9 (8.0)
   Western Asian                                                    1 (1.3)       0 (0.0)       1 (0.7)        0 (0.0)       1 (0.4)       0 (0.0)       1 (0.5)       0 (0.0)
   Other                                                            1 (1.3)       1 (0.4)       2 (1.4)        0 (0.0)       2 (0.8)       0 (0.0)       1 (0.5)       1 (0.9)
  Psychiatric profile, mean (SD)[\*](#tf1-1){ref-type="table-fn"}                                                                                                      
   Composite Cognitive Score                                        23.9 (8.0)    22.5 (6.6)    22.6 (7.3)     23.0 (6.7)    23.2 (7.1)    21.1 (6.2)    23.4 (7.5)    21.9 (5.8)
   HAMD~17~ total (visit 1)                                         22.5 (3.4)    22.2 (3.8)    22.2 (3.6)     22.3 (3.8)    22.3 (3.7)    21.9 (3.8)    22.5 (3.8)    21.7 (3.4)
   HAMD~17~ total (randomisation)                                   19.2 (5.0)    18.7 (4.6)    19.0 (4.7)     18.7 (4.7)    18.8 (4.7)    19.4 (4.7)    18.9 (5.0)    18.7 (4.2)
   GDS total                                                        17.5 (7.5)    17.7 (7.0)    17.4 (7.1)     17.9 (7.1)    17.6 (7.2)    17.9 (6.8)    18.1 (7.1)    16.8 (7.1)
   Duration of current episode, weeks                               59.8 (89.3)   54.3 (85.3)   61.8 (101.5)   50.7 (71.4)   56.9 (88.6)   48.8 (71.6)   50.3 (70.0)   65.2 (108.7)
   Number of previous episodes                                      4.5 (6.3)     5.8 (16.4)    5.9 (17.7)     5.1 (11.2)    5.3 (13.9)    6.4 (17.8)    4.7 (9.9)     6.7 (20.3)
   VAS overall pain severity                                        21.9 (21.6)   34.4 (27.6)   22.5 (21.7)    38.3 (28.3)   30.6 (26.3)   35.0 (28.9)   32.9 (27.7)   28.3 (24.7)
   SF-36 physical component                                         46.0 (11.2)   40.0 (10.3)   44.6 (11.1)    39.0 (9.8)    42.3 (10.8)   37.3 (9.9)    42.5 (10.7)   39.9 (10.9)
   SF-36 mental component                                           31.6 (12.3)   32.4 (10.5)   32.3 (12.0)    32.2 (10.1)   32.1 (10.8)   33.0 (12.0)   31.7 (11.1)   33.1 (10.8)

Total sample sizes for variables shown range from 304 to 311.

Efficacy in cognitive measures (primary)
----------------------------------------

[Figure 1](#fig01){ref-type="fig"} presents the MC from baseline in the composite cognitive score for all randomised patients and by subgroups based on presence or absence of the comorbidities. Duloxetine significantly improved cognitive performance compared with placebo in all randomised patients (1.95 vs. 0.76, p = 0.013). Duloxetine-treated patients showed significantly greater improvement compared with placebo-treated patients in the composite cognitive score for patients having any of the three medical comorbidities (2.15 vs. 0.60; p = 0.006). A significant difference did not occur for patients without a medical comorbidity (duloxetine, 1.38; placebo, 0.96; p = 0.724). However, there were no statistically significant treatment-by-comorbidity interactions for any comorbidity (p = 0.266) or for any of the individual comorbidities.

![Effects of duloxetine compared with placebo on composite cognitive score: mean change analysis in all randomised patients and in baseline comorbidity subgroups](ijcp0061-1283-f1){#fig01}

Efficacy in depression measures
-------------------------------

Results from the MC analyses of the depression efficacy measures are shown in [Figure 2A,B](#fig02){ref-type="fig"}. Patients treated with duloxetine had significantly greater improvement in both GDS and HAMD~17~ total scores than did patients treated with placebo. There were no statistically significant treatment-by-comorbidity interactions for either GDS or HAMD~17~ total scores. Moreover, CGI-S findings were consistent with findings for GDS and HAMD~17~ total scores (data not shown).

![(A) Effects of duloxetine compared with placebo on GDS total score: mean change analysis in all randomised patients and in baseline comorbidity subgroups. (B) Effects of duloxetine compared with placebo on HAMD~17~ total score: mean change analysis in all randomised patients and in baseline comorbidity subgroups](ijcp0061-1283-f2){#fig02}

Duloxetine-treated patients had significantly greater rates of response (37.3% vs. 18.6%, p \< 0.001) and remission (27.4% vs. 14.7%, p = 0.014) compared with placebo-treated patients. There were no statistically significant treatment-by-comorbidity interactions for either response or remission rate, suggesting that comorbidity status did not affect the treatment effect of duloxetine in achieving response or remission.

Efficacy in pain measures
-------------------------

In all randomised patients, there was a significantly greater improvement in VAS for back pain (−5.72 vs. 1.41, p = 0.008) and time in pain while awake (−6.36 vs. 0.99, p = 0.028) for duloxetine compared with placebo. The treatment difference for other pain measures, including overall pain, headache, shoulder pain and pain interference with daily activities, was not statistically significant. There were no statistically significant treatment-by-comorbidity interactions for headache and shoulder pain. However, there were statistically significant treatment-by-comorbidity interactions: overall pain for the arthritis (interaction, p = 0.037; with arthritis, duloxetine, −7.97; placebo, 1.29, p = 0.052; without arthritis, duloxetine, −1.27; placebo, −6.13, p = 0.241) and vascular (interaction, p = 0.077; with vascular disease, duloxetine, 1.81; placebo, 11.59, p = 0.059; without vascular disease, duloxetine, −7.79; placebo, −7.13, p = 0.868) comorbidities; interference with daily activities (interaction, p = 0.057; with arthritis, duloxetine, −4.85; placebo, 3.52, p = 0.067; without arthritis, duloxetine, −1.53; placebo, −6.75, p = 0.198) and back pain (interaction, p = 0.001; with arthritis, duloxetine, −8.79; placebo, 5.96, p \< 0.001; without arthritis, duloxetine, −2.08; placebo, −6.64, p = 0.227) for arthritis comorbidity; and time in pain while awake for vascular comorbidity (interaction, p = 0.090; with vascular disease, duloxetine, −2.05; placebo, 10.01, p = 0.048; without vascular disease, duloxetine, −8.24; placebo, −5.30, p = 0.477). To each of these five significant interactions, duloxetine was more effective compared with placebo in patients with the comorbidity when compared with those without the comorbidity.

Efficacy in SF-36 improvement
-----------------------------

In all randomised patients, there was a significantly greater improvement with duloxetine treatment compared with placebo in the SF-36 physical component summary (0.61 vs. −1.14, p = 0.047), but not for the SF-36 mental component summary (8.33 vs. 6.18, p = 0.117). There were no statistically significant treatment-by-comorbidity interactions for the SF-36 physical component summary ([Figure 3](#fig03){ref-type="fig"}). However, there was a significant treatment-by-comorbidity interaction for the SF-36 mental component summary with respect to vascular comorbidity (p =0.077); a statistically significant benefit of duloxetine over placebo was shown for patients with vascular comorbidity (8.91 vs. 3.04, p = 0.015), but not for those without vascular comorbidity (8.17 vs. 7.85, p = 0.864). In addition, there was a significant treatment-by-comorbidity interaction (p = 0.044) for physical functioning for vascular comorbidity (with vascular disease, duloxetine, 1.96; placebo, 4.66, p = 0.519; without vascular disease, duloxetine, 4.76; placebo, −3.60, p = 0.005) and for social functioning (p = 0.016) for arthritis comorbidity (with arthritis, duloxetine, 16.58; placebo, 4.64, p = 0.004; without arthritis, duloxetine, 11.62; placebo, 15.44, p = 0.432).

![Effects of duloxetine compared with placebo on SF-36 Physical Component Summary: mean change analysis in all randomised patients and in baseline comorbidity subgroups](ijcp0061-1283-f3){#fig03}

Tolerability
------------

Tolerability was analysed in all randomised patients and by any comorbidity subgroups. Overall discontinuation rates for any reason did not significantly differ between the duloxetine and placebo groups (21.7% vs. 23.1%, p = 0.775). However, the rate of discontinuation caused by lack of efficacy was significantly greater among placebo-treated patients than duloxetine-treated patients (9.6% vs. 2.9%; p = 0.026). The incidence of discontinuation caused by AEs was similar in both treatment groups (9.7% vs. 8.7%, p = 0.839). Nausea was the only AE leading to discontinuation that occurred at a statistically significantly different rate in duloxetine-than in placebo-treated patients, and the rate of discontinuation caused by this AE was lower for duloxetine than for placebo (0.5% vs. 3.8%, p = 0.044). There were no significant treatment-by-comorbidity interactions for incidences of discontinuation because of an AE.

TEAEs for which the incidence among duloxetine-treated patients was at least 5.0% and twice the placebo rate are presented in [Table 2](#tbl2){ref-type="table"}. The incidence of at least one TEAE was similar for duloxetine and placebo (70.0% vs. 64.4%, p = 0.367) in overall patients; there was a statistically significant treatment-by-comorbidity interaction (p = 0.030) for any comorbidity. For patients with any comorbidity, the incidences were similar for the two treatment groups, but for patients with no comorbidity, the incidence was higher for duloxetine than for placebo (76.9% vs. 50.0%; p = 0.022). Of these TEAEs, those occurring significantly more frequently for duloxetine than for placebo in overall patients were dry mouth (14.5% vs. 1.9%; p \< 0.001), nausea (12.6% vs. 3.8%; p = 0.014) and diarrhoea (8.2% vs. 1.9%; p = 0.042). There was no statistically significant treatment-by-comorbidity interaction for the incidence of any of the common TEAEs.

###### 

Treatment-emergent adverse events, overall and by any comorbidity subgroup

                                      Placebo   Duloxetine 60 mg QD                                     
  ------------------------- --------- --------- --------------------- ----- ------------ -------------- -----------
  Patients with ≥ 1 TEAEs   Overall   104       67 (64.4)             207   145 (70.0)   0.367          --
                            Yes       78        54 (69.2)             155   105 (67.7)   0.882          **0.030**
                            No        26        13 (50.0)             52    40 (76.9)    **0.022**      
  Dry mouth                 Overall   104       2 (1.9)               207   30 (14.5)    **\< 0.001**   --
                            Yes       78        2 (2.6)               155   23 (14.8)    0.003          0.440
                            No        26        0 (0.0)               52    7 (13.5)     0.088          
  Nausea                    Overall   104       4 (3.8)               207   26 (12.6)    **0.014**      --
                            Yes       78        3 (3.8)               155   19 (12.3)    0.055          0.933
                            No        26        1 (3.8)               52    7 (13.5)     0.257          
  Constipation              Overall   104       5 (4.8)               207   21 (10.1)    0.131          --
                            Yes       78        4 (5.1)               155   12 (7.7)     0.588          0.311
                            No        26        1 (3.8)               52    9 (17.3)     0.151          
  Dizziness                 Overall   104       3 (2.9)               207   17 (8.2)     0.087          --
                            Yes       78        3 (3.8)               155   13 (8.4)     0.275          0.345
                            No        26        0 (0.0)               52    4 (7.7)      0.295          
  Diarrhoea                 Overall   104       2 (1.9)               207   17 (8.2)     **0.042**      --
                            Yes       78        2 (2.6)               155   12 (7.7)     0.150          0.366
                            No        26        0 (0.0)               52    5 (9.6)      0.163          
  Fatigue                   Overall   104       3 (2.9)               207   13 (6.3)     0.279          --
                            Yes       78        1 (1.3)               155   10 (6.5)     0.105          0.135
                            No        26        2 (7.7)               52    3 (5.8)      1.000          
  Somnolence                Overall   104       1 (1.0)               207   11 (5.3)     0.067          --
                            Yes       78        1 (1.3)               155   7 (4.5)      0.274          0.455
                            No        26        0 (0.0)               52    4 (7.7)      0.295          

Significant (p ≤ 0.05) within-stratum treatment comparison p-values are bolded if the treatment-by-subgroup p-value is statistically significant (p ≤ 0.10).

Significant (p ≤ 0.10) treatment-by-subgroup p-values are bolded.

Discussion
==========

These results support the efficacy and tolerability of duloxetine in the treatment of elderly patients with MDD with or without common comorbid medical conditions. Overall, duloxetine-treated patients demonstrated significantly greater improvement compared with placebo-treated patients on outcome measures that included the composite cognitive score, depression severity measures and several of the SF-36 and VAS measures. Few significant treatment-by-comorbidity subgroup interactions occurred for these efficacy variables, or for AEs reported as the reason for discontinuation or common TEAEs, suggesting that the efficacy and tolerability of duloxetine in the treatment of depression in elderly patients were not largely affected by comorbidity status. Specifically, the results regarding the impact of comorbid medical illness on treatment outcomes in MDD were consistent regardless of whether the outcomes were measured with the GDS, the HAMD~17~ or CGI-S.

This study reaffirms the high prevalence of medical comorbidity in patients with late-life depression because nearly 75% of patients participating in the study met criteria for the presence of medical comorbidity. This proportion may be an underestimate, as patients with unstable acute medical illness were excluded from the study. Moreover, we measured only three common medical comorbidities; a higher prevalence of comorbidities likely would have been measured if more medical illnesses were recorded. Most of the findings in patient baseline characteristics were as expected; for instance, mean age was higher in patients with vascular comorbidity and VAS overall pain severity was higher in patients with arthritis. The fact that patients with vascular comorbidity had more previous episodes and longer duration of current episode of MDD may be attributed to certain vascular-related factors contributing to depression, including brain damage from infarcts or microvascular effects ([@b6]). Such factors are in line with the notion that physical illness and depression tend to have mutually worsening effects.

Although cognitive deficits in patients with MDD, especially the elderly patients, have been demonstrated in many studies ([@b27]), antidepressant drugs do not routinely improve cognition in such patients ([@b32],[@b33]). Follow-up studies of patients treated for MDD have shown that some patients demonstrate poor performance on cognitive tests even after treatment ([@b34]). In the present study, duloxetine-treated patients demonstrated similar improvement on the composite cognitive score with or without a comorbid illness. However, even though the treatment-by-subgroup interaction was not significant, patients with any of the three comorbid illnesses and treated with duloxetine showed a significantly greater improvement on the composite cognitive score compared with the placebo group. In the subgroup without a comorbid illness, duloxetine did not show significantly greater improvement than did placebo. Although the explanation for this lesser improvement in the group without a comorbid illness is unknown, it could be an artifact as a result of the relatively small number of patients in that subgroup. Nevertheless, the augmenting effect of duloxetine on 5-HT and NE activity may make it particularly beneficial in treating the cognitive deficits associated with depression as imbalance or deficiency in either 5-HT or NE neurotransmission has been found to contribute to cognitive deficits ([@b16],[@b17]). Treatment of depression with tricyclics, such as imipramine, has been found to improve cognitive function despite the detrimental anticholinergic effects ([@b35]).

The comorbidity of pain and depression in elderly patients is of special significance when considering the high prevalence of pain in this age group ([@b36],[@b37]). A direct relationship between pain severity and depression has been identified in elderly patients with chronic pain ([@b37]). In the present analyses, duloxetine demonstrated statistically significant improvements in two of the six pain measures: the VAS for back pain and time in pain while awake. These findings suggest that duloxetine may be effective in relieving pain caused by chronic conditions, including arthritis and vascular disease. Duloxetine has been shown to be effective in the management of diabetic peripheral neuropathic pain ([@b38],[@b39]) and in improving painful physical symptoms independent of improvement of depression severity in younger MDD populations ([@b40]). However, patients enrolled in this study were not selected specifically for pain and the pain reported was generally not severe. It is possible that more or less robust efficacy for duloxetine might be observed in patients with depression who have a higher baseline pain severity.

The present results are consistent with findings in acute treatment studies of antidepressants, including SSRIs, in medically ill patients with depression ([@b41]--[@b45]). A review of 18 studies in mostly non-elderly patients with depression and having at least one physical disorder found that antidepressant treatment was significantly better than placebo in improving depressive symptoms ([@b42]). In an 8-week study, older patients treated with sertraline had similar responses on the HAMD~17~ total score, CGI-S and CGI-I whether they had a comorbid medical illness or not ([@b41]). In a study by Small et al. ([@b45]), geriatric patients with major depression and with none, 1, 2, 3, 4 or ≥ 5 chronic physical illnesses were treated with fluoxetine 20 mg/day or placebo for 6 weeks. The analyses showed that the number of chronic illnesses did not have an influence on treatment outcomes. One outcome of interest from that study was the finding that patients with a greater number of illnesses had a greater response to fluoxetine, whereas the opposite was found with the placebo group, although the total number of patients was somewhat small in the subgroup with no chronic illnesses (*N* = 73). A similar finding was found with elderly patients with vascular illnesses treated with sertraline ([@b44]). In a pooled analysis of two studies, patients were placed into three groups: with hypertension, with vascular illness and no hypertension, and no hypertension or cardiovascular illness. The patients in the first two groups showed a consistently greater percentage of responders on the HAMD and CGI-I compared with the third group.

In the present study, the absolute response and remission rates were relatively low, which may be attributed to the short 8-week study duration, as well as the fixed dosing schedule. Nevertheless, the relative advantages of duloxetine in response and remission rates were convincing, as evidenced by the fact that they were twice the placebo rates and the differences were statistically significant. In general, depression trials in the elderly patients are more difficult to show positive efficacy results for active treatments over placebo than do trials in the general population ([@b46]). In a recent placebo-controlled study of fluoxetine and venlafaxine in patients ≥ 65 years with MDD, there were no significant differences among the three treatment groups in the change of HAMD~21~, MADRS or CGI scores, and the difference in the proportion of remitters at the last on-therapy visit was not statistically significant ([@b47]). Similarly, in a group of community-dwelling elderly patients ≥ 75 years with depression, citalopram was not more effective than placebo for the treatment of depression ([@b48]). However, in two larger studies in patients ≥ 60 years with depression, sertraline or fluoxetine was more effective than placebo ([@b41],[@b49]). The remission rates in these studies were generally low, and the differences between treatment groups were small (20--35% for active treatments, 18--33% for placebo).

Duloxetine was well tolerated in patients with medical comorbidity as well as in patients with no medical comorbidity. More importantly, common TEAEs and discontinuation caused by AEs were comparable to those seen in younger, more general populations receiving duloxetine ([@b50]). This is also in line with what has been found with the SSRI sertraline ([@b41]). A study of patients with late-life depression and having vascular disease, diabetes mellitus or arthritis actually had a lower percentage of patients experiencing the most common TEAEs than did patients with no comorbid illnesses ([@b41]). In addition, the percentage of patients discontinuing for any reason, or specifically for AEs, were also lower in the comorbid illness group. In the pooled analysis by Krishnan et al. ([@b44]), there were also no differences between the groups with comorbid illness compared with the group with no comorbid illness in rates of TEAEs and in discontinuation caused by TEAEs.

A number of limitations should be kept in mind when evaluating the results of this study. First, the study excluded patients with acute and unstable medical conditions that are common among elderly populations. The 8-week study duration of the trial may be relatively short for a study in elderly patients. Roose and Sackeim ([@b51]) have suggested that a minimum of 12-week duration may be necessary to identify response or remission. Patients had limited-dose flexibility during the study, which may not be typical of clinical practice for an elderly population. Comorbid medical conditions could also be based on medical histories and patient report rather than a diagnosis by a physician during the physical examination. Finally, the number of patients was relatively small in the diabetes group.

In conclusion, results from this placebo-controlled trial support the hypothesis that duloxetine is effective and well tolerated in treating elderly patients with MDD. The duloxetine vs. placebo treatment effect on cognition, depression and quality-of-life in elderly patients with MDD was not largely affected by the presence or absence of one or more of the three medical comorbidities (vascular disease, diabetes and arthritis) that frequently occur in the elderly population.
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